Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Combined Chemo-immunotherapy With Cisplatin-pembrolizumab and Radiation for Unresectable Vulvar Squamous Cell Carcinoma

NCT04430699 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT04430699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04430699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Combined Chemo-immunotherapy With Cisplatin-pembrolizumab and Radiation for Unresectable Vulvar Squamous Cell Carcinoma
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 29, 2020
Completion date
January 30, 2028
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

vulvar cancer, vulvar squamous cell carcinoma